Curasight will broadcast a live audio webcast online, available in the investor section of their website 48 hours after airing. During the TD Cowen conference, Curasight's management will hold one-on-one meetings with investors and industry stakeholders. This conference is a significant event where healthcare companies engage with institutional investors and large pharmaceutical companies through scheduled meetings and discussions. Curasight A/S is developing uTREAT®, a clinical-stage radioligand therapy targeting uPAR, which is involved in tumor growth and spread, and is present in over 85% of solid tumors. Their platform also includes uTRACE®, a uPAR-PET imaging agent that aids in patient selection and tumor targeting, tested in over 450 patients across various trials. The uPAR platform is based on extensive research from Copenhagen University Hospital and the University of Copenhagen. For more information, contact CEO Ulrich Krasilnikoff via email or visit their website.

Innan transaktionen ägde aktieägaren 5,29% av aktiekapitalet och rösträtterna i företaget. Efter transaktionen innehar aktieägaren nu 4,85%, vilket motsvarar ett ägande under 5%. Detta meddelande publiceras i enlighet med de gällande reglerna för större aktieägaranmälningar på Spotlight Stock Market. För mer information om Curasight, kontakta Ulrich Krasilnikoff, VD, via e-post på uk@curasight.com eller besök www.curasight.com.